8th December
2009
Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA)…

Yup, couldn’t agree more. And I’d like to add that you’ve got a great colour scheme on your site, I suffer with colour blindness and many webmasters don’t give us a second thought!